All In Biotech

Drug Trial Radar · NCT07109726

A Phase 1/2 Trial of TER-2013 in Patients With Solid Tumors Harboring AKT/PI3K/PTEN Pathway Alterations

Last checked: Nov 19, 2026Latest source record: Oct 28, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

248

Planned (sponsor's estimate)

Start

Sep 23, 2025

Primary completion

Dec 30, 2028

Study completion Feb 28, 2029

Sponsor

Lead sponsor
Terremoto Biosciences Inc.Industry
Sponsor type
Industry
First posted
Aug 7, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Non randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a Phase 1/2, open-label, multicenter study evaluating the safety, tolerability, pharmacokinetics, pharmacodynamics and anti-tumor activity of TER-2013 in patients with advanced solid tumors harboring AKT/PI3K/PTEN pathway alterations.

Conditions

  • Breast Cancer
  • Endometrial Cancer
  • Ovarian Cancer
  • Lung Squamous Cell Carcinoma
  • Head and Neck Squamous Cell Carcinoma
  • Esophageal Squamous Cell Carcinoma
  • Solid Tumor
  • Cervical Cancer

Interventions

  • TER-2013Drug

    Oral Capsules

  • Fulvestrant injectionDrug

    Fulvestrant 500 mg Intramuscular Injection

  • TER-2013Drug

    Oral tablets

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of Patients who Experience Dose-Limiting ToxicityTime frame: 28 Days
  2. Number of patients who experience a treatment-related adverse eventTime frame: Up to 2 years
  3. Objective Response Rate as assessed by RECIST v1.1Time frame: Up to 2 years
  4. Duration of Response as assessed by RECIST v1.1Time frame: Up to 2 years
  5. Progression-Free survival as assessed by RECIST v1.1Time frame: Up to 2 years
  6. Over-all survival as assessed by RECIST v1.1Time frame: Up to 2 years

Locations

25 sites in 5 countries. Site status is shown where the registry gives one.

  • City of Hope

    Duarte, California · Recruiting

  • City of Hope, Irvine

    Irvine, California · Recruiting

  • Florida Cancer Specialists - Lake Nona

    Orlando, Florida · Recruiting

  • City of Hope, Chicago

    Zion, Illinois · Recruiting

  • Massachusetts General Hospital

    Boston, Massachusetts · Recruiting

  • Mayo Rochester

    Rochester, Minnesota · Recruiting

  • Washington Univ. School of Medicine

    St Louis, Missouri · Recruiting

  • Nebraska Cancer Specialists

    Omaha, Nebraska · Recruiting

  • Carolina BioOncology Institute

    Huntersville, North Carolina · Withdrawn

  • UH Cleveland Medical Center

    Cleveland, Ohio · Recruiting

  • Sarah Cannon Nashville

    Nashville, Tennessee · Recruiting

  • NEXT Oncology

    Austin, Texas · Active not recruiting

  • MD Anderson Cancer Center

    Houston, Texas · Recruiting

  • START Center for Cancer Research

    San Antonio, Texas · Recruiting

  • START Center for Cancer Research

    West Valley City, Utah · Recruiting

  • NEXT Oncology

    Fairfax, Virginia · Recruiting

  • Froedtert & MCW Cancer Center

    Milwaukee, Wisconsin · Recruiting

  • START Dublin, Mater Misericordiae University Hospital

    Dublin, Republic of Ireland, Ireland · Not yet recruiting

  • Centro Clínico Académico de Braga

    Braga, Portugal, Portugal · Not yet recruiting

  • START Lisboa

    Lisbon, Portugal, Portugal · Recruiting

  • PanOncology Trials

    San Juan, Puerto Rico · Recruiting

  • START Research Center at Hospital HM Nou Delfos

    Barcelona, Spain, Spain · Recruiting

  • Hospital Universitario General de Catalunya

    Barcelona, Spain, Spain · Recruiting

  • Md Anderson Cancer Center Madrid-Hospiten

    Madrid, Spain, Spain · Not yet recruiting

  • START Madrid, Fundacion Jimenez Diaz

    Madrid, Spain, Spain · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.